What an SGLT2 inhibitor does
SGLT2 (sodium-glucose cotransporter-2) is a protein in your kidneys that normally reclaims glucose from urine and returns it to your bloodstream. An SGLT2 inhibitor — the drug class nicknamed “gliflozins” — blocks that protein, so instead of being reabsorbed, extra sugar leaves the body in your urine. The result is lower blood glucose. These are once-daily oral pills used in type 2 diabetes, and some are also prescribed for heart and kidney protection.
Why it comes up alongside GLP-1s
SGLT2 inhibitors sit in the same broad conversation as GLP-1 medications because both are modern options for type 2 diabetes — but they work in completely different places. A GLP-1 drug acts on gut hormones and the brain’s appetite signals; an SGLT2 inhibitor works downstream at the kidneys. Because their mechanisms don’t overlap, they’re sometimes used together, and both are often discussed in the context of insulin resistance and blood-sugar control. The other common pairing you’ll hear about is the DPP-4 inhibitor, which works on the incretin system instead.
What to keep in mind
An SGLT2 inhibitor is not primarily a weight-loss medication — any weight change tends to be modest, and the main job is blood sugar (plus heart and kidney benefits for some people). If your interest is the appetite and weight effects people describe, those belong to the GLP-1 class. Which medication, or combination, fits your situation is a decision for your clinician, who can weigh your blood sugar, other conditions, and goals.